Immuneering plans Phase 2 trial of atebimetinib plus PD-1 blockade in lung cancer patients

By Public Technologies
  • Immuneering flagged preclinical results showing atebimetinib can strengthen PD-1 checkpoint blockade in RAS-mutant tumor models.
  • Findings will be presented at the SITC annual meeting on Nov. 6, 2026.
  • Data supports a planned Phase 2 study pairing atebimetinib with PD-1 blockade in lung cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900PRIMZONEFULLFEED9838124) on October 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk